Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnicare Inc.

Division of CVS Health Corp.
www.omnicare.com

Latest From Omnicare Inc.

What Is An Acceptable Drug Discount? DOJ and Industry Disagree

Government contends a price reduction is the only discount exception to the Anti-Kickback Statute; PhRMA says this interpretation puts companies at risk of criminal liability for other discount arrangements.

Legal Issues Reimbursement

P&G Asks For Higher Class Action Floor In Align Class Certification Appeal

Procter & Gamble petitions the Supreme Court to overturn a decision giving class action certification to a complaint alleging the firm deceived consumers with its “snake oil” Align probiotic. If the court overturns the lower court, the action could make class action certifications more difficult.

Dietary Supplements Wellness

Pharma M&A Booming In First Eight Months Of The Year

The year 2015 could give 2014 a run for the money in terms of biopharma M&A deal value. From January through August, 18 deals were signed with an upfront value of more than $1bn, representing a total upfront value of $133bn.

BioPharmaceutical Deals

Biopharma Quarterly Dealmaking Statistics, Q2 2015

Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.

BioPharmaceutical Deals
See All

Company Information

UsernamePublicRestriction

Register